LY-503,430

drugbox
IUPAC_name = (R)-4'- [1-fluoro-1-methyl-2-(propane-2-sulfonylamino)-ethyl] -biphenyl-4-carboxylic acid methylamide

---

width = 200
CAS_number = 625820-83-9
synonyms = LY-503,430
ATC_prefix =
ATC_suffix =
PubChem =
DrugBank =
C = 20 | H = 25 | F = 1 | N = 2 | O = 3 | S = 1
molecular_weight = 392.49 g/mol
smiles = CC(C)S(=O)(=O)NCC(F)(C)c(cc2)ccc2-c(cc1)C(=O)NC
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status = Investigational New Medicine
routes_of_administration = oral

LY-503,430 is an ampakine drug developed by Eli Lilly. [O'Neill MJ, Murray TK, Clay MP, Lindstrom T, Yang CR, Nisenbaum ES. LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease. "CNS Drug Reviews". 2005 Spring;11(1):77-96. [http://www.ncbi.nlm.nih.gov/pubmed/15867954 PMID 15867954] ]

LY-503,430 produces both nootropic and neuroprotective effects, reducing brain damage caused by 6-hydroxydopamine or MPTP and also increasing levels of the neurotrophic factor BDNF in the brain, particularly in the substantia nigra, hippocampus and striatum. [Murray TK, Whalley K, Robinson CS, Ward MA, Hicks CA, Lodge D, Vandergriff JL, Baumbarger P, Siuda E, Gates M, Ogden AM, Skolnick P, Zimmerman DM, Nisenbaum ES, Bleakman D, O'Neill MJ. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. "Journal of Pharmacology and Experimental Therapeutics". 2003 Aug;306(2):752-62. [http://www.ncbi.nlm.nih.gov/pubmed/12730350 PMID 12730350] ] [Ryder JW, Falcone JF, Manro JR, Svensson KA, Merchant KM. Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. "Journal of Pharmacology and Experimental Therapeutics". 2006 Oct;319(1):293-8. [http://www.ncbi.nlm.nih.gov/pubmed/16803862 PMID 16803862] ] It is orally active and the main application it is currently being developed for is treatment of Parkinson's Disease although it has also been proposed to be useful in the treatment of Alzheimer's Disease, depression and schizophrenia. [O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES. AMPA receptor potentiators for the treatment of CNS disorders. "Current Drug Targets. CNS and Neurological Disorders". 2004 Jun;3(3):181-94. [http://www.ncbi.nlm.nih.gov/pubmed/15180479 PMID 15180479] ] [O'Neill MJ, Witkin JM. AMPA receptor potentiators: application for depression and Parkinson's disease. "Current Drug Targets". 2007 May;8(5):603-20. [http://www.ncbi.nlm.nih.gov/pubmed/17504104 PMID 17504104] ]

References